The Column Group — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)Matthew Jacobson(Director)David J. Earp(President & CEO)Paul Park(Executive Officer)
BoardThilo Schroeder(Director)in
Board seatJohn JoseyJames EvangelistaPeter Svennilson· per SEC Form D
Co-investorsBerkeley CatalystLifeforce CapitalMission Bay CapitalMission BiocapitalNextech InvestPandect Bioventures+1 more
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inDaniel Becker(Director)
Board seatJohn Josey· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersRA Capital
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)Maureen E. Hillenmeyer(Executive Officer, Director)Maureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Board seatDavid Goeddel· per SEC Form D
Co-investorsB3 HoldingNextech InvestSoftBank Vision Fund8VCCasdin CapitalTwo Sigma Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.